Abstracts tagged "rituximab and scleroderma"

Abstract Number: 2904 • 2016 ACR/ARHP Annual Meeting
Rituximab in Systemic Sclerosis-Interstitial Lung Disease, a Case Series of 18 Patients
Gul Guzelant¹, Melike Melikoglu¹, Benan Musellim², Deniz Demir Yilmaz², Izzet Fresko¹, Emire Seyahi¹, Gulen Hatemi¹, Serdal Ugurlu¹ and Vedat Hamuryudan¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Pulmonary Medicine, Istanbul, Turkey
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc). Immunosuppressives such as cyclophosphamide (CYC) and mycophenolate mophetil (MMF) are used in…
Abstract Number: 834 • 2015 ACR/ARHP Annual Meeting
The Efficacy of Rituximab in Systemic Sclerosis Joint Disease: A Pilot Study
Helena Borrell Paños¹, Javier Narváez², Juan José Alegre³, Ivan Castellvi⁴, Gloria Albert Espi³, Sergi Heredia¹, Elide Toniolo⁴ and Joan Miquel Nolla¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Between 16 and 20% of patients with systemic sclerosis (SS) have arthritis, which is occasionally erosive. In addition, between 1 and 5% of patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].